Abstract
The purpose of the study is to review the clinical features, treatments, and outcomes of neonatal neuroblastoma (NB). A retrospective analysis was performed on 42 patients with NB between January 1994 and December 2011. MYCN amplification was detected in nine tumor samples. The ratio of unfavorable histology to favorable histology was 1:2 in NB patients. The 5-year overall survival (OS) of NB patients was 85.7%. The 5-year OS in patients in the operation group was 83.3%, chemotherapy group was 83.3%, and the "wait-and-see" group was 100% (P=0.04). Overall, the prognosis was favorable, except in patients with elevated MYCN amplification or vanillylmandelic acid. NB patients were more sensitive and vulnerable to chemotherapy and operation. The "wait-and-see" strategy should be highlighted in the treatment of NB.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
